Toulouse, April 10th, 2018 – For its third year of operation, the Toulouse-based company EnobraQ, which specializes in biotechnology, is strengthening its development and announcing changes in its structure. It notably opens up its capital to three major research structures: INRA, INSA and CNRS and confirms a second round of fundraising in 2 years for a cumulative amount of 4.9 million euros. Sofinnova Partners, Auriga Partners, Irdinov and SuperNovaInvest are reaffirming their confidence. This financial support will make it possible to pursue development on three axes, and particularly yield improvement of certain industrial productions by up to 20%. EnobraQ recognized by his peers.
Through this new fundraising and the entry into the capital of big names in research such as INRA, INSA and CNRS, EnobraQ is demonstrating the viability of its projects over the long term. Founded by private investors at the end of 2015, EnobraQ was one of the first startups to be accompanied by Toulouse White Biotechnology (TWB) on the development of innovative projects and one of the first to receive direct support from its supervisory bodies. 2 million euros raised to materialize breakthrough innovations
With discoveries made over the past two years, EnobraQ is currently working on a project to improve the output of industrial productions by up to 20%. Thanks to its cutting-edge research on the use of CO2, it is also developing a lactic acid production process which could thus contribute to reducing the dependency on fossil products such as oil, to save resources needed for food but also help reduce carbon footprint. Finally, the company focuses on the optimization of photosynthesis through a process demonstrating a significant improvement of the enzyme allowing the fixation of CO2. In the long run, this discovery could have a positive and lasting impact on food security worldwide. Accelerating industrialization of biotechnology processes In its new development phase, EnobraQ aims to generalize the use of CO2 as industrial feedstock. Today we are entering a strategic phase of our development. Our expertise of the RuBisCO in industrial biotechnology, the most widespread protein in the world, allows us to target the nutrition, bioplastics and agri-food markets. This new fundraising and the support of three major French public research centers will enable us to expand our fields of action and lead to the implementation of sustainable processes” explains Christophe Dardel, Chief Executive Officer. About EnobraQ
EnobraQ is a start-up created in 2015, from a pre-competitive research project supported by Toulouse White Biotechnology (TWB). Concerned with ecological and economic considerations, EnobraQ develops breakthrough technologies that use CO2 and target markets as diverse as nutrition, agri-food, cosmetics, pharmacology and bioplastics. More information at : Click here for the PDF version: CP EnobraQ – Fund Raising April 2018

Media Contact

Mélissa Pontéry / Aurélie Vérin
Tél : +33 (0)5 32 11 07 36 / / @melissapontery


Ramonville Saint Agne, April 27th 2017 – EnobraQ is proud to announce the appointment of Christophe Dardel as new CEO of EnobraQ. He is replacing Michael Krel who has been acting CEO since EnobraQ’s inception late 2015. Consequently, Michael will resume his duty at Sofinnova and will also act as board member of EnobraQ. Christophe’s mission will be to crystalize the company’s ambition to unlock the use of CO2 as an industrial fermentation feedstock enabling large commodity chemicals to be produced in a sustainable manner, both economically and ecologically. Christophe Dardel was previously the President of DSM Biomedical located in the USA where he was responsible for leading the business’s global activities that included the acquisition of Kensey Nash, a leading regenerative medicine company. Christophe was also Board Member of Actamax® a DSM/DuPont Joint Venture. Before joining DSM Biomedical in May 2010, Christophe served for eight years as President of DSM Dyneema, the inventor and manufacturer of Dyneema®, the world’s strongest fiber™. In 2003 he was also appointed board member of Nippon Dyneema Co., Ltd – a joint venture of Toyobo and DSM. Prior to joining DSM in 2002, Christophe held several positions within 3M and E. I. du Pont de Nemours Christophe Dardel adds “ I am very proud to join EnobraQ to bring its vision to reality: transforming the world by enabling the use of CO2 as a carbon feedstock for the chemical industry. By doing so with an industrially proven microorganism, we really think we can have an impact on the global greenhouse gases i ssue Leopold Demideleer, chairman of the board, concludes: “ We are very excited to welcome Christophe at EnobraQ. His outstanding international business experience is now needed to boost our small start-up to the next development stage”. About EnobraQ
EnobraQ is a French metabolic engineering start up founded in 2015 leveraging patented pending breakthrough technologies developed within the Toulouse White Biotech cluster (TWB). EnobraQ is unlocking the use of CO2 as an industrial fermentation feedstock enabling large commodity chemicals to be produced in a sustainable manner, both economically and ecologically. Click here for the PDF version: PR – Nomination Christophe Dardel_FV

Contacts Presse

Mélissa Pontéry / Aurélie Vérin
Tél : +33 (0)5 32 11 07 36 / / @melissapontery


Toulouse, April 19, 2016. EnobraQ, a biotechnology company developing CO2-based industrial fermentation processes, announces it has secured a 2.9 M€ seed financing round lead by Auriga Partners and Sofinnova Partners. Also participating in the round were IRDInov and CEA Investissement. Proceeds will be allocated towards EnobraQ’s research and development plan targeting an advanced proof of concept before the end of 2017. Founded in 2015 by Sofinnova Partners, following a research project financed by the Toulouse White Biotechnology cluster, EnobraQ is developing a fermentation process using CO2 as its sole carbon source for the production of molecules of interest for the chemical industry. New technological solutions are needed to fight climate change through substituting petroleum products for cleaner alternatives. In this context, EnobraQ’s disruptive approach is to use yeast for CO2 capture and production of chemical compound, thereby significantly reducing greenhouse gases. It provides a unique, innovative response for reducing the threat and seizing the opportunity: feeding the yeasts from its technology with CO2 and decarbonized hydrogen to carry out customized chemical syntheses on an industrial scale
« This successful financing is a major milestone for the company. We are very pleased and honored to have been able to convince several prestigious seed funds to help us in our prospective development” said Leopold Demiddeleer, EnobraQ’s chairman. “Even though we are still very early stage, and hence a very risky proposition, the exceptional potential of the company has convinced our investors” adds Leopold Demiddeleer. About EnobraQ
EnobraQ is a biotechnology company that develops carbon dioxide based fermentation processes to provide bio-based alternatives to fossil fuel-derived chemicals. The company was founded in 2015 following a research project within the Toulouse White Biotechnology cluster. About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together 12 highly experienced investment professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a founding and lead investor in start-ups and corporate spin-offs, and has backed nearly 500 companies over more than 40 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.5 billion under management. For more information, please visit: About AURIGA IV Bioseeds:
AURIGA IV Bioseeds is a seed investment fund of more than €40M, supported by the Banque Publique d’Investissement and the European Investment Fund. The fund is focused on supporting technological companies emerging from knowledge and know-how developed in Infectiology and Microbiology. AURIGA IV Bioseeds is managed by AURIGA Partners, an independent venture firm based in 18 avenue de Matignon 75008 Paris France and registered with the register of commerce and companies of Paris under number 419 156 351. AURIGA Partners invests in high technology projects bringing innovation to market. About IRDInov:
IRDInov is a seed-capital Fund managed by IRDI Gestion based in Toulouse (France). Since its launch in 2012, with financial backing from FNA (French National Seed Fund) managed by BPI France, IRDI, Midi-Pyrénées and Aquitaine regions, and regional banks and industrial actors, IRDInov focuses its investments on seed-capital for technological projects generated from private and public research institutions. IRDInov has the capability to invest up to 3 M€ by project in the south-west of France. About CEA Investissement
CEA Investissement, a subsidiary of the CEA, is a specialist in seed investment in technology companies. Its proximity to public research laboratories and the venture capital industry has made it a key player in launching and financing startup companies in France. To date, it has funded over 50 companies. With 15 years’ experience in seed investment, CEA Investissement has generated several successful exits, including companies such as TRACIT, ULIS, MOVEA and FERMENTALG. The investment in EnobraQ was made through the Amorçage Technologique Investissement (ATI) fund, managed by CEA Investissement. The CEA, BPI (using the FNA), EDF, SAFRAN and BIOMERIEUX are investors in ATI.